Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Neuromotus: A novel neuroplastic treatment for Phantom Limb Pain

Reference number
Coordinator CHALMERS TEKNISKA HÖGSKOLA AKTIEBOLAG - Institutionen för signaler och system
Funding from Vinnova SEK 1 620 000
Project duration September 2016 - August 2018
Status Completed

Purpose and goal

This project enabled the clinical validation of a novel technology for the treatment of PLP, namely Neuromotus. Neuromotus overcomes technological limitations of current treatments while it remains non-invasive, low-risk, and apt for bilateral amputations. Moreover, Neuromotus offers a more engaging and effective therapy than currently available options. In this project, Neuromotus became a fully integrated device approved to be independently operated by the end user (clinicians and patients). The CE marking of Neuromotus was initiated and expected in early 2019.

Expected results and effects

PLP is a deteriorating condition for which there is currently no effective treatment; it tends to become chronic; and, it reduces the quality of life of patients and closer relatives. A successful treatment would not only provide relief and restore quality of life, but would also facilitate the reintegration of patients as productive members of society, which in turn would reduce the costs associated with the disability. The results of this project showed that Neuromotus is effective in reducing PLP and can be used by clinicians and patients independently from engineering staff.

Planned approach and implementation

This project was a truly multidisciplinary endeavor. It was coordinated by Chalmers University of Technology and conducted in close collaboration with three major hospitals in Sweden (Stockholm, Örebro, and Gothenburg) and one industrial partner (Integrum AB). An approved, safe, robust, and user-friendly device was developed by the consortium and used successfully in clinical environments and by patients at home.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2016-02290

Page statistics